Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Double-blind randomized controlled clinical trial (RCT) of low-dose lenalidomide in the
treatment of elderly patients (> 60 years of age) with mild to moderate clinical signs of
COVID-19 disease from the Hospital Universitario of Getafe.
The study will include patients of both sexes (> 60 years of age) with mild to moderate
clinical presentation of COVID-19 (ROX index > 10). Subjects will be randomly assigned to the
experimental arm with lenalidomide (5 mg/24h, day 1, 3 and 5) or to the controlled arm. Other
concomitant medication for the treatment of COVID-19 will be also considered.